SingleCell Biotechnology has developed a diagnostic platform for intractable cancers that can be used to assess the aggressiveness of an individual patient’s cancer and find new drugs to stop the mechanisms of recurrence in solid tumors.
SingleCell Biotechnology has developed a diagnostic platform for intractable cancers that can be used to assess the aggressiveness of an individual patient’s cancer and find new drugs to stop the mechanisms of recurrence in solid tumors.
The failure rate of new drugs for glioblastoma (GBM, form of brain cancer) is about 99% or higher. Recurrence and mortality of GBM and other solid tumor cancers develops from highly resistant stem cell phenotypes that remain after primary treatment. Currently there are no adequate tools to study these lethal cell phenotype populations. Our company has developed a platform of diagnostic tools to study these cell phenotypes. Now, drug development companies can test their drugs and compounds to see if they affect stem cell phenotypes in addition to primary tumor cells. If drugs or compounds are effective in killing or stopping both primary tumor cells and stem cell phenotypes, there is a much greater chance of having a successful drug candidate that will make a difference in patients' lives.
Awarded CPRIT SEED Grant ($2.5M) to optimize assays and demonstrate usefulness in drug development for GBM.
Successfully tested on primary patient GBM tumor cells direct from the operating room to demonstrate use as a personalized diagnostic device.
Platform successfully tested on Glioblastoma (brain) cancer AND breast cancer PDX cell lines to demonstrate usefulness as a drug discovery tool.
Used platform to demonstrate effectiveness (or non-effectiveness) of current drugs and radiation on dormant and migrating cells.
Demonstrated use case of a repurposed drug using the platform.
Prototype stage completed
Awarded CPRIT Grant for $2.5M to further the optimization of the plaform assays and demonstrate drug development in finding new biomarkers to combat difficult cancers.
4 well device version of platform devices made ready for production, past the prototype stage.
Platform successfully tested with primary tumor cells direct from operating room to show that it has the ability to be used as a diagnostic device.
Demonstrated that the platform can be used to identify re-purposed drugs that can be used to enhance or provide improved treatment outcomes.
Used platform to demonstrate how current drugs and radiation have little to no effect on migrating and dormant cancer cells. Further showing that current treatments targeting rapidly dividing cells leave this lethal population of non-dividing cells behind.
Platform successfully demonstrated on prototype devices to demonstrate single cell dormancy, migration, and clonogenic assays with both Glioblastoma (brain) cancer and breast cancer patient derived cell lines.
SingleCell Biotechnology selected to receive CPRIT Grant Award for $2.5M to further develop their ground breaking assays and demonstrate their usefulness in drug development.
